MediWound to Present at Upcoming Investor Conferences in September

Rhea-AI Summary

MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company specializing in wound management, announced investor presentations in September 2020. CEO Sharon Malka will present at three virtual conferences: the Wells Fargo Virtual Healthcare Conference on September 10, H.C. Wainwright Annual Global Investment Conference on September 14, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21. MediWound is known for its innovative products, including NexoBrid and EscharEx, targeting severe burns and hard-to-heal wounds.

YAVNE, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, MediWound’s Chief Executive Officer, will present at the following investor conferences in September:

2020 Wells Fargo Virtual Healthcare Conference
Date: September 10, 2020
Time: 8:40am ET
Format: Virtual Presentation

H.C. Wainwright 22^nd Annual Global Investment Conference
Date: Monday, September 14, 2020
Time: 11:30am ET
Format: Virtual Presentation

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Monday, September 21, 2020
Time: 3:20pm ET
Format: Virtual Presentation

About MediWound Ltd.

MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue. The product has received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health. MediWound’s second innovative product, EscharEx® is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid. In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com.

Contacts:		Jeremy Feffer
Boaz Gur-Lavie		Jeremy Feffer
Chief Financial Officer		Managing Director, LifeSci Advisors
MediWound Ltd.		212-915-2568
ir@mediwound.com		jeremy@lifesciadvisors.com

FAQ

When will MediWound present at the Wells Fargo Virtual Healthcare Conference?

MediWound will present at the Wells Fargo Virtual Healthcare Conference on September 10, 2020, at 8:40am ET.

What is the date of the H.C. Wainwright Annual Global Investment Conference for MediWound?

The H.C. Wainwright Annual Global Investment Conference will take place on September 14, 2020, at 11:30am ET.

What time is MediWound's presentation at the Oppenheimer Fall Healthcare Summit?

MediWound's presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is scheduled for September 21, 2020, at 3:20pm ET.

What products does MediWound focus on?

MediWound focuses on developing products for severe burns and chronic wounds, including NexoBrid and EscharEx.

What is NexoBrid, and how is it used?

NexoBrid is a biopharmaceutical product that non-surgically removes burn eschar while preserving healthy tissue.